Drug intelligence / Profile preview

LIO-106

Development stage: Preclinical
Lead developer: Lymbus Oncology
Modality: Small Molecules

Overview

LIO-106 is a novel small-molecule therapeutic developed by Lymbus Oncology, with support from BioGenerator and Cadre Biosciences. It functions as an ATR inhibitor, designed to enhance the efficacy of immune checkpoint inhibitors in cancer patients who do not respond to current treatments. In 2020, LIO-106 was in preclinical development.

Targets

ATR (ATR serine/threonine kinase)

Beyond the preview

Go deeper on LIO-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIO-106.

Explore the full profile